Results 11 to 20 of about 72,883 (309)
Acta Dermato-Venereologica, 2023 The aim of this study was to compare the efficacy and safety of treatment with Janus kinase inhibitors for alopecia areata, measured by change in Severity of Alopecia Tool (SALT) score.
Farnam Barati Sedeh +4 more
doaj +2 more sources
Epidemiological Trends in Alopecia Areata at the Global, Regional, and National Levels
Frontiers in Immunology, 2022 BackgroundNo comprehensive studies have been published on the global burden of alopecia areata since 2010.ObjectiveWe aimed to measure the global, regional, and national incidence of alopecia areata and disability-adjusted life-years (DALYs) by age, sex,
Haifeng Wang, Lifang Pan, Yanfeng Wu
doaj +2 more sources
Adiponectin as a novel biomarker of disease severity in alopecia areata
Scientific Reports, 2021 The frequent coexistence of obesity and metabolic syndrome in patients with alopecia areata may indicate the common pathogenetic pathway in these conditions with an important role of adipokines.
Anna Stochmal +6 more
doaj +2 more sources
Alopecia Areata Associated with Localized Vitiligo [PDF]
Case Reports in Dermatology, 2010 Alopecia areata is a common cause of noncicatricial alopecia that occurs in a patchy, confluent or diffuse pattern. It may occur as a single, self-limiting episode or may recur at varying intervals over many years. The association of alopecia areata with
Shankarling D. Kuchabal, D.S. Kuchabal
doaj +4 more sources
Janus Kinase Inhibitors for Alopecia Areata
JAMA Network Open, 2023 This systematic review and meta-analysis assesses outcomes from 7 randomized clinical trials, including changes in severity and adverse events, associated with use of JAK inhibitors among adults with alopecia areata.
Ming Liu +6 more
semanticscholar +2 more sources
Treatment with an Anti-CD44v10-Specific Antibody Inhibits the Onset of Alopecia Areata in C3H/HeJ Mice [PDF]
, 2000 A murine CD44v10-neutralizing antibody has been reported to impair delayed-type hypersensitivity reactions. Because alopecia areata is characterized by a delayed-type hypersensitivity-like T cell mediated immune response, we addressed the question ...
Pia Freyschmidt‐Paul +7 more
openalex +4 more sources
American Journal of Clinical Dermatology, 2023 Alopecia areata (AA) is an autoimmune disease that causes patchy hair loss on the scalp, face, and body. Baricitinib is a Janus kinase inhibitor that is approved to treat AA in several countries, based on results from two studies, BRAVE-AA1 and BRAVE-AA2.
O. Kwon +10 more
semanticscholar +1 more source
JAMA dermatology, 2023 Key Points Question What is the contemporary prevalence and incidence of alopecia areata (AA), alopecia totalis, and alopecia universalis in the US? Findings In this cohort study of a nationwide US employer-sponsored insurance population, AA prevalence ...
A. Mostaghimi +7 more
semanticscholar +1 more source
Alopecia Areata: An Updated Review for 2023
Journal of Cutaneous Medicine and Surgery, 2023 Alopecia areata is an immunemediated condition leading to nonscarring alopecia of the scalp and other hairbearing areas of the body. It affects up to 2% of the global population.1 It can affect all ages, but the prevalence appears higher in children ...
C. Sibbald
semanticscholar +1 more source
Baricitinib for the Treatment of Alopecia Areata
Drugs, 2023 Alopecia areata (AA) is a relapsing, chronic, immune-mediated disease characterized by nonscarring, inflammatory hair loss that can affect any hair-bearing site. AA clinical presentation is heterogeneous.
Egídio Freitas +2 more
semanticscholar +1 more source